• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环miR-21和miR-29a作为小儿胆汁淤积性肝病疾病严重程度和病因的标志物

Circulating miR-21 and miR-29a as Markers of Disease Severity and Etiology in Cholestatic Pediatric Liver Disease.

作者信息

Goldschmidt Imeke, Thum Thomas, Baumann Ulrich

机构信息

Department of Paediatric Hepatology and Gastroenterology, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover 30625, Germany.

Integrated Research and Treatment Centre Transplantation (IFB-Tx), Hannover Medical School, Hannover 30625 Germany.

出版信息

J Clin Med. 2016 Feb 25;5(3):28. doi: 10.3390/jcm5030028.

DOI:10.3390/jcm5030028
PMID:26927196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4810099/
Abstract

Circulating microRNAs have been investigated as markers of disease severity in a variety of conditions. We examined whether circulating miR-21 and miR-29a could serve as markers of hepatic fibrosis and disease etiology in children with various liver diseases. Circulating miR-21 and miR-29a were determined in 58 children (21 female, age 0.1-17.8 (median 9.8) years)) with chronic liver disease and compared to histological grading of hepatic fibrosis. 22 healthy children served as controls for circulating miRNAs. Levels of circulating miR-21 appeared to be age-dependent in healthy children. Children with biliary atresia had significantly higher levels of miR-21 compared both to healthy controls and to age-matched children with other cholestatic liver disease. Circulating miR-29a levels in biliary atresia children did not differ from healthy controls, but tended to be higher than in age-matched children with other cholestatic liver disease. Neither miR-21 nor miR-29a correlated well with hepatic fibrosis. Circulating miR-21 and miR-29a levels can potentially serve as non-invasive diagnostic markers to differentiate biliary atresia from other cholestatic disease in infancy. They do not appear suitable as non-invasive markers for the degree of hepatic fibrosis in an unselected cohort of children with various liver diseases. The discriminating effect regarding neonatal cholestasis should be followed up in a prospective longitudinal study.

摘要

循环微RNA已被作为多种疾病严重程度的标志物进行研究。我们研究了循环miR-21和miR-29a是否可作为各种肝病患儿肝纤维化及疾病病因的标志物。对58例(21例女性,年龄0.1 - 17.8岁(中位数9.8岁))慢性肝病患儿测定了循环miR-21和miR-29a,并与肝纤维化的组织学分级进行比较。22例健康儿童作为循环微RNA的对照。健康儿童中循环miR-21水平似乎与年龄有关。与健康对照以及年龄匹配的其他胆汁淤积性肝病患儿相比,胆道闭锁患儿的miR-21水平显著更高。胆道闭锁患儿的循环miR-29a水平与健康对照无差异,但往往高于年龄匹配的其他胆汁淤积性肝病患儿。miR-21和miR-29a均与肝纤维化无良好相关性。循环miR-21和miR-29a水平有可能作为无创诊断标志物,用于区分婴儿期的胆道闭锁与其他胆汁淤积性疾病。在未经过挑选的患有各种肝病的儿童队列中,它们似乎不适宜作为肝纤维化程度的无创标志物。关于新生儿胆汁淤积的鉴别作用应在前瞻性纵向研究中进行随访。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecca/4810099/2d2c5147613b/jcm-05-00028-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecca/4810099/e79b05643c5a/jcm-05-00028-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecca/4810099/d9bbbcd32e47/jcm-05-00028-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecca/4810099/2d2c5147613b/jcm-05-00028-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecca/4810099/e79b05643c5a/jcm-05-00028-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecca/4810099/d9bbbcd32e47/jcm-05-00028-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ecca/4810099/2d2c5147613b/jcm-05-00028-g003.jpg

相似文献

1
Circulating miR-21 and miR-29a as Markers of Disease Severity and Etiology in Cholestatic Pediatric Liver Disease.循环miR-21和miR-29a作为小儿胆汁淤积性肝病疾病严重程度和病因的标志物
J Clin Med. 2016 Feb 25;5(3):28. doi: 10.3390/jcm5030028.
2
MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice.微小 RNA-29a 减轻内质网和自噬异常可抵抗梗阻性黄疸诱导的小鼠纤维化。
Exp Biol Med (Maywood). 2018 Jan;243(1):13-21. doi: 10.1177/1535370217741500. Epub 2017 Nov 6.
3
MicroRNA-29a Alleviates Bile Duct Ligation Exacerbation of Hepatic Fibrosis in Mice through Epigenetic Control of Methyltransferases.微小RNA-29a通过对甲基转移酶的表观遗传调控减轻小鼠胆管结扎所致的肝纤维化恶化
Int J Mol Sci. 2017 Jan 18;18(1):192. doi: 10.3390/ijms18010192.
4
MicroRNA-29a mitigation of toll-like receptor 2 and 4 signaling and alleviation of obstructive jaundice-induced fibrosis in mice.微小RNA-29a减轻小鼠 toll 样受体2和4信号传导并缓解梗阻性黄疸诱导的纤维化
Biochem Biophys Res Commun. 2018 Feb 12;496(3):880-886. doi: 10.1016/j.bbrc.2018.01.132. Epub 2018 Jan 31.
5
MicroRNA-29a is a key regulon that regulates BRD4 and mitigates liver fibrosis in mice by inhibiting hepatic stellate cell activation.MicroRNA-29a 是一个关键的调节因子,通过抑制肝星状细胞的激活,调节 BRD4,减轻小鼠的肝纤维化。
Int J Med Sci. 2019 Jan 1;16(2):212-220. doi: 10.7150/ijms.29930. eCollection 2019.
6
Microarray Study of Pathway Analysis Expression Profile Associated with MicroRNA-29a with Regard to Murine Cholestatic Liver Injuries.关于小鼠胆汁淤积性肝损伤,与微小RNA-29a相关的通路分析表达谱的微阵列研究。
Int J Mol Sci. 2016 Mar 1;17(3):324. doi: 10.3390/ijms17030324.
7
Activation of Mir-29a in Activated Hepatic Stellate Cells Modulates Its Profibrogenic Phenotype through Inhibition of Histone Deacetylases 4.活化肝星状细胞中Mir-29a的激活通过抑制组蛋白脱乙酰基酶4调节其促纤维化表型。
PLoS One. 2015 Aug 25;10(8):e0136453. doi: 10.1371/journal.pone.0136453. eCollection 2015.
8
Association of circulating microRNA-122 and microRNA-29a with stage of fibrosis and progression of chronic hepatitis in Labrador Retrievers.循环微小RNA-122和微小RNA-29a与拉布拉多猎犬肝纤维化分期及慢性肝炎进展的相关性
J Vet Intern Med. 2019 Jan;33(1):151-157. doi: 10.1111/jvim.15366. Epub 2018 Dec 11.
9
MicroRNA-29a Suppresses CD36 to Ameliorate High Fat Diet-Induced Steatohepatitis and Liver Fibrosis in Mice.miR-29a 通过抑制 CD36 改善高脂饮食诱导的小鼠脂肪性肝炎和肝纤维化。
Cells. 2019 Oct 22;8(10):1298. doi: 10.3390/cells8101298.
10
[Significance of microRNA 216a, 324-5p and 29a expression in peripheral blood in patients with acute pancreatitis and their correlation with liver injury].[微小RNA 216a、324 - 5p和29a在外周血中的表达在急性胰腺炎患者中的意义及其与肝损伤的相关性]
Zhonghua Yi Xue Za Zhi. 2020 Jul 21;100(27):2126-2131. doi: 10.3760/cma.j.cn112137-20200103-00016.

引用本文的文献

1
Circulating Extracellular Vesicles Contain Liver-Derived RNA Species as Indicators of Severe Cholestasis-Induced Early Liver Fibrosis in Mice.循环细胞外囊泡包含肝来源的 RNA 物种,作为小鼠严重胆汁淤积性早期肝纤维化的标志物。
Antioxid Redox Signal. 2022 Mar;36(7-9):480-504. doi: 10.1089/ars.2021.0023. Epub 2022 Jan 4.
2
Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting , , and .通过靶向 、 和 抑制肝癌的转移行为。
Int J Mol Sci. 2021 Jun 1;22(11):6001. doi: 10.3390/ijms22116001.
3
New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics.

本文引用的文献

1
Potential of extracellular microRNAs as biomarkers of acetaminophen toxicity in children.细胞外微小RNA作为儿童对乙酰氨基酚毒性生物标志物的潜力。
Toxicol Appl Pharmacol. 2015 Apr 15;284(2):180-7. doi: 10.1016/j.taap.2015.02.013. Epub 2015 Feb 21.
2
Circulating microRNAs as noninvasive diagnostic biomarkers of liver disease in children with cystic fibrosis.循环微RNA作为囊性纤维化患儿肝病的非侵入性诊断生物标志物。
J Pediatr Gastroenterol Nutr. 2015 Feb;60(2):247-54. doi: 10.1097/MPG.0000000000000600.
3
Solid tumors of childhood display specific serum microRNA profiles.
miR-29a在肝细胞癌中的作用新见解:对机制及治疗诊断的启示
J Pers Med. 2021 Mar 18;11(3):219. doi: 10.3390/jpm11030219.
4
The Emerging Role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in Modulating Oxidative Stress, Inflammation, and Beyond.miRNAs 在非酒精性脂肪性肝病中的新兴作用:miRNA-29a 调节氧化应激、炎症及其他方面的作用亮点。
Cells. 2020 Apr 22;9(4):1041. doi: 10.3390/cells9041041.
5
: a potential therapeutic target and promising biomarker in tumors.是肿瘤的一个潜在治疗靶点和有前途的生物标志物。
Biosci Rep. 2018 Feb 8;38(1). doi: 10.1042/BSR20171265. Print 2018 Feb 28.
6
Diagnostic and therapeutic potentials of microRNAs in cholangiopathies.微小RNA在胆管疾病中的诊断和治疗潜力
Liver Res. 2017 Jun;1(1):34-41. doi: 10.1016/j.livres.2017.03.003. Epub 2017 Apr 26.
7
Serum MicroRNA Levels as a Noninvasive Diagnostic Biomarker for the Early Diagnosis of Hepatitis B Virus-Related Liver Fibrosis.血清 microRNA 水平作为乙型肝炎病毒相关肝纤维化早期诊断的无创性诊断生物标志物。
Gut Liver. 2017 Nov 15;11(6):860-869. doi: 10.5009/gnl16560.
儿童实体瘤呈现出特定的血清微小RNA谱。
Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):350-60. doi: 10.1158/1055-9965.EPI-14-0669. Epub 2014 Nov 21.
4
MicroRNA-29a protects against acute liver injury in a mouse model of obstructive jaundice via inhibition of the extrinsic apoptosis pathway.微小RNA-29a通过抑制外源性凋亡途径在梗阻性黄疸小鼠模型中预防急性肝损伤。
Apoptosis. 2014 Jan;19(1):30-41. doi: 10.1007/s10495-013-0909-4.
5
Role of miR-21 in the pathogenesis of atrial fibrosis.miR-21 在心房纤维化发病机制中的作用。
Basic Res Cardiol. 2012 Sep;107(5):278. doi: 10.1007/s00395-012-0278-0. Epub 2012 Jul 4.
6
Circulating microRNA is a biomarker of biliary atresia.循环 microRNA 是胆道闭锁的生物标志物。
J Pediatr Gastroenterol Nutr. 2012 Oct;55(4):366-9. doi: 10.1097/MPG.0b013e318264e648.
7
microRNA are Central Players in Anti- and Profibrotic Gene Regulation during Liver Fibrosis.微小RNA是肝纤维化过程中抗纤维化和促纤维化基因调控的核心参与者。
Front Physiol. 2012 Mar 19;3:49. doi: 10.3389/fphys.2012.00049. eCollection 2012.
8
MicroRNA profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia.microRNA 谱分析鉴定 miR-29 作为实验性胆道闭锁中疾病相关途径的调节剂。
J Pediatr Gastroenterol Nutr. 2012 Feb;54(2):186-92. doi: 10.1097/MPG.0b013e318244148b.
9
Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21.转化生长因子-β诱导的内皮细胞向间充质细胞转化部分由 microRNA-21 介导。
Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):361-9. doi: 10.1161/ATVBAHA.111.234286. Epub 2011 Nov 17.
10
Circulating microRNA is a biomarker of pediatric Crohn disease.循环 microRNA 是小儿克罗恩病的生物标志物。
J Pediatr Gastroenterol Nutr. 2011 Jul;53(1):26-33. doi: 10.1097/MPG.0b013e31822200cc.